Enhanced 2-deoxy-2- ( 18 F) fluoro-D-glucose (FDG) Uptake on PET-CT Due to a Benign Condition and Hodgkin Ã¢ÂÂ s LymphomaWendi G. O’Connor1, Monte S. Willis1,2* and Arif Sheikh3
- *Corresponding Author:
- Monte S. Willis
Associate Professor, McAllister Heart Institute
Department of Pathology and Laboratory Medicine
University of North Carolina, 111 Mason Farm Road
MBRB 2340B, Chapel Hill, NC 27599, USA
E-mail: [email protected]
Received date January 13, 2013; Accepted date March 25, 2013; Published date March 30, 2013
Citation: O’Connor WG, Willis MS, Sheikh A (2013) Enhanced 2-deoxy-2- (18F) fluoro-D-glucose (FDG) Uptake on PET-CT Due to a Benign Condition and Hodgkin’s Lymphoma. J Nucl Med Radiat Ther 4:142. doi: 10.4172/2155-9619.1000142
Copyright: © 2013 O’Connor WG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The utility of FDG PET-CT in documenting malignant disease has been demonstrated for many disease processes. However, non-malignant causes for FDG PET-CT enhancement exist. Here we present an example of a 12 year-old male diagnosed with Hodgkin’s lymphoma that underwent an FDG PET-CT for evaluation and initial staging. The scan demonstrated disease in the chest and abdomen in addition to focal uptake in the left distal tibia that was considered to represent a focus of disease. Unexpectedly, as the disease was treated, the focal uptake in the leg did not decrease prompting additional CT and conventional radiograph imaging, which found that the lesion was consistent with Non-Ossifying Fibroma (NOF). This case illustrates that FDG PET-CT can identify both malignant disease and benign bone lesions that may masquerade as metastatic disease.